AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-14. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
=== "Revolution within a Revolution": 1987–1998 === The late 1980s saw a series of liberalizing economic reforms within Libya designed to cope with the decline in oil revenues. In May 1987, Gaddafi announced the start of the "Revolution within a Revolution", which began with reforms to industry and agriculture and saw the re-opening of small business. Restrictions were placed on the activities of the Revolutionary Committees; in March 1988, their role was narrowed by the newly created Ministry for Mass Mobilization and Revolutionary Leadership to restrict their violence and judicial role, while in August 1988 Gaddafi publicly criticized them. In March, hundreds of political prisoners were freed, with Gaddafi falsely claiming that there were no further political prisoners in Libya. In June, Libya's government issued the Great Green Charter on Human Rights in the Era of the Masses, in which 27 articles laid out goals, rights, and guarantees to improve the situation of human rights in Libya, restricting the use of the death penalty and calling for its eventual abolition. Many of the measures suggested in the charter would be implemented the next year, although others remained inactive. Also in 1989, the government founded the Al-Gaddafi International Prize for Human Rights, to be awarded to figures from the Third World who had struggled against colonialism and imperialism; the first year's winner was South African anti-apartheid activist Nelson Mandela.
== Development and applications == nanoCLAMPs were developed in the laboratories of Nectagen. nanoCLAMP phage display libraries were constructed that contained variations on 16 surface amino acids in three loops with function diversities of approximately 109 variants. These libraries have been screened for binders to target proteins and peptides, typically yielding between 1 and 30 unique binders to the target. Purified nanoCLAMPs containing a single C-terminal cysteine can be easily conjugated to halo-acetyl activated agarose resins under native or denaturing conditions, and the resulting thioether bond renders the resins leach-proof. Targets can be purified to apparent homogeneity in a single-step. The polyol-responsive nature of the resins allows the targets to be eluted with 0.75 M ammonium sulfate and 40% propylene glycol at pH 7.9, conditions which have been shown to preserve native structure and protein complexes. nanoCLAMPs have been produced that target green fluorescent protein (GFP), mCherry, SUMO (SMT3), NusA, avidin, NeutrAvidin, maltose-binding protein (MBP), thioredoxin 1, beta-galactosidase, SlyD, and others. Typical binding capacities of resins range from 1 to 4 mg/ml resin. Because nanoCLAMPs readily refold, nanoCLAMP resins can be regenerated multiple times using guanidinium chloride to clean the resin.
=== Laboratory synthesis === The chemical synthesis of DMT has been described. It can be synthesized through several possible pathways from different starting materials. The two most commonly encountered synthetic routes are through the reaction of indole with oxalyl chloride followed by reaction with dimethylamine and reduction of the carbonyl functionalities with lithium aluminium hydride to form DMT. The second commonly encountered route is through the N,N-dimethylation of tryptamine using formaldehyde followed by reduction with sodium cyanoborohydride or sodium triacetoxyborohydride. Sodium borohydride can be used but requires a larger excess of reagents and lower temperatures due to it having a higher selectivity for carbonyl groups as opposed to imines. Procedures using sodium cyanoborohydride and sodium triacetoxyborohydride (presumably created in situ from cyanoborohydride though this may not be the case due to the presence of water or methanol) also result in the creation of cyanated tryptamine and beta-carboline byproducts of unknown toxicity while using sodium borohydride in absence of acid does not. Bufotenine, a plant extract, can also be synthesized into DMT. Alternatively, an excess of methyl iodide or methyl p-toluenesulfonate and sodium carbonate can be used to over-methylate tryptamine, resulting in the creation of a quaternary ammonium salt, which is then dequaternized (demethylated) in ethanolamine to yield DMT. The same two-step procedure is used to synthesize other N,N-dimethylated compounds, such as 5-MeO-DMT.
Habiger of the United States Air Force who was Commander in Chief from 1996 to 1998 of United States Strategic Command; Richard Lugar, former senator for Indiana; Ash Carter, later United States Secretary of Defense, from 2015 to 2017; the US spent around $2.5 billion sending former nuclear missiles back to Russia in the early 1990s; Matthew Bunn, writer on nuclear security; the Soviet Union had 8 main radar sites in its early warning system - a main site in Latvia was dismantled, and nine satellites became three; General Vladimir Dvorkin (Russian), who wanted missiles to be less 'launchable', known as de-alerting; Lieutenant-General William Eldridge Odom, who was sceptical of 1990s meetings between US and Russian generals; Alexei Yablokov (Russian and the danger of suitcase nuclear devices, and Alexander Lebed; Armimex and a June 1997 commercial plot; William Cohen, United States Secretary of Defense from 1997 to 2001. Written by June Cross, directed by Dan Chambers, produced by David Dugan, made by Windfall Films and WGBH. Shown on PBS Frontline on 23 February 1999
== Class B peptidomimetics == This class of peptidomimetics encompasses peptides with a large number of non-natural amino acids, major backbone modifications or larger non-natural building fragments that resemble the conformation of a particular peptide binding motif. Examples involve D-peptide and peptidic foldamers such as beta-peptides.
Sources: en.wikipedia.org
=== Schizophrenia === Persistent KOR signaling has been implicated in the pathophysiology of schizophrenia, in the generation of both positive and negative symptoms, and as an explanation for treatment-resistant psychosis. Mechanistically, chronic KOR activation produces long-term sensitization of dopamine D2 receptors in the striatum, which manifests as supersensitized D2 receptor states that amplify phasic dopamine signaling and hyperresponsivity to dopaminergic stimuli. This mechanism could interact with the underlying excessive striatal dopamine transmission in schizophrenia, potentiating positive symptoms including delusions and hallucinations, and explaining why dopamine D2 receptor antagonists (antipsychotics) remain effective. Apart from striatal mechanisms, KOR signaling modulates cortical glutamate and GABA homeostasis through KOR activation on GABAergic terminals of dynorphin-expressing neurons in prefrontal cortex which suppresses GABA release and disrupting the balance of cortical inhibition-excitation that might drive cognitive dysfunction and negative symptoms. Thus, KOR antagonism may provide a complementary strategy to D2 antagonism by simultaneously reducing D2 receptor sensitization to normalize striatal dopamine responsivity and restoring cortical inhibition-excitation balance to ameliorate cognitive dysfunction. The receptor availability also predicts severity of anhedonia in schizophrenia.
== Administration of ACAM2000 == The ACAM2000 vaccine is produced from the vaccinia virus, which is sufficiently closely related to smallpox to provide immunity, but the ACAM2000 vaccine cannot cause smallpox because it does not contain the smallpox virus. Other vaccines containing live viruses include measles, mumps, rubella, polio and chickenpox. The vaccine is administered using a bifurcated stainless steel needle. The needle is dipped into the vaccine solution and used to prick the skin several times in the upper arm. The vaccinia virus will begin to grow at the injection site. It will cause a localized infection, with a red itchy sore produced at the vaccination site within three to four days. If the infection occurs, that is an indication that the vaccine was successful. Ultimately, the sore turns into a blister and then dries up. A scab forms and then falls off in the third week, leaving a small scar behind.
In 2008, Air Chief Marshal Sir Glenn Torpy Head of the Royal Air Force, for his part in Operation Telic / Operation Iraqi Freedom. Lieutenant General Sir James Dutton, Royal Marines, "in recognition of meritorious, gallant and distinguished services during coalition operations in Afghanistan". Major General Colin Boag, British Army, "in recognition of gallant and distinguished services during coalition operations in Iraq" (March 2008). Lieutenant General James Bucknall, British Army, "in recognition of gallant and distinguished services during coalition operations in Iraq" (July 2009). Major General Mohamed Elkeshky, Egyptian Army Defense, Military, Naval and Air Attaché to the United States. (2013). In 2011, Vice Admiral Tomohisa Takei, Japan Maritime Self-Defense Force, "as recognition for Takei's exceptional leadership and expertise in maturing and expanding the JMSDF and U.S. Navy partnership during his role as director of operations and plans department, JMSDF Maritime Staff Office from April 2008 to July 2010". In 2013, Lieutenant General Walter Souza Braga Netto, Brazilian Army, Military Attaché to the United States of America. "For exceptionally meritous conduct in the performance of outstanding services from March 2011 to May 2013. In 2014, Air Commodore David Best, United Kingdom Royal Air Force. "For exceptionally meritorious service as Director of Air Operations, International Security Assistance Force, from December 2010 to December 2011". In 2014, Major General Brett Cairns, Canadian Air Force, NORAD J3.
Like other AASs, oxandrolone is an agonist of the androgen receptor, similar to androgens such as testosterone and DHT. The relative binding affinity of oxandrolone for the androgen receptor is about 0.3% of that of metribolone. Activation of the androgen receptor stimulates protein synthesis, which increases muscle growth, lean body mass, and bone mineral density. Compared to testosterone and many other AASs, oxandrolone is less androgenic relative to its strength as an anabolic. Oxandrolone has as much as six times the anabolic potency of testosterone and has significantly reduced androgenic potency in comparison: oxandrolone exhibits significantly lower virilizing androgenic properties compared to testosterone, with a relative androgenic potency of only 5%. Compared to methyltestosterone, oxandrolone has about 322 to 633% of the anabolic potency and 24% of the androgenic potency. The reduced ratio of anabolic to androgenic activity of oxandrolone motivated its medical use in children and women because less androgenic effect implies less risk of virilization. The bodybuilding community also considers this fact when choosing between AASs. As of 2003 and 2011 Oxandrolone was thought to be "uniquely" far less hepatotoxic than other 17α-alkylated AASs, which was thought to be due to differences in metabolism. This turned out not to be the case in the long run, which is why it was taken off the US market in 2023.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.